Covered recipient · General Payments record
DAVID R SPIGEL
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$26,969.32
67 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $16,283.31 | 4 |
| Travel and Lodging | $8,776.88 | 6 |
| Food and Beverage | $1,909.13 | 57 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $12,751.71 | 14 |
| GlaxoSmithKline, LLC. | $7,240.50 | 3 |
| ABBVIE INC. | $2,213.03 | 4 |
| PFIZER INC. | $1,950.00 | 1 |
| AstraZeneca UK Limited | $1,271.11 | 2 |
| AstraZeneca Pharmaceuticals LP | $327.61 | 7 |
| JAZZ PHARMACEUTICALS INC. | $311.02 | 1 |
| Gilead Sciences, Inc. | $171.57 | 2 |
| Janssen Biotech, Inc. | $144.94 | 7 |
| Astellas Pharma US Inc | $76.87 | 3 |
| Merck Sharp & Dohme LLC | $60.18 | 3 |
| Daiichi Sankyo Inc. | $51.73 | 2 |
| AVYXA PHARMA, LLC | $46.38 | 2 |
| Blueprint Medicines Corporation | $42.32 | 1 |
| SpringWorks Therapeutics, Inc. | $41.96 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $29.77 | 1 |
| Regeneron Healthcare Solutions, Inc. | $28.17 | 1 |
| EMD Serono, Inc. | $24.52 | 1 |
| Stemline Therapeutics Inc. | $24.16 | 1 |
| GENZYME CORPORATION | $23.76 | 1 |
| Incyte Corporation | $21.10 | 1 |
| Genentech USA, Inc. | $19.69 | 1 |
| TerSera Therapeutics LLC | $18.88 | 1 |
| ARRAY BIOPHARMA INC | $17.60 | 1 |
| Novocure Inc. | $16.08 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $14.97 | 1 |
| Celgene Corporation | $14.87 | 1 |
| Novartis Pharmaceuticals Corporation | $14.82 | 1 |
Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAVID R SPIGEL
NPI 1427074210 · CMS profile ID 291623
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
NASHVILLE, TN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1427074210?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAVID R SPIGEL, NPI 1427074210, CMS profile ID 291623. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427074210?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). DAVID R SPIGEL, NPI 1427074210, CMS profile ID 291623. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427074210?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- DAVID R SPIGEL, NPI 1427074210, CMS profile ID 291623, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1427074210?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
67 matching records · $26,969.32 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–67 of 67.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | $26.76 | 04/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238363569 | CMS |
| Daiichi Sankyo Inc. | $26.02 | 04/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197056247 | CMS |
| TerSera Therapeutics LLC | $18.88 | 04/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244055176 | CMS |
| SpringWorks Therapeutics, Inc. | $20.36 | 04/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232171477 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.65 | 04/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184562287 | CMS |
| PUMA BIOTECHNOLOGY, INC. | $14.97 | 03/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251741594 | CMS |
| Daiichi Sankyo Inc. | $25.71 | 03/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197054759 | CMS |
| Gilead Sciences, Inc. | $21.96 | 03/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234505629 | CMS |
| Novocure Inc. | $16.08 | 03/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251155001 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.51 | 03/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214774925 | CMS |
| Blueprint Medicines Corporation | $42.32 | 03/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235815527 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.05 | 02/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184562279 | CMS |
| Novartis Pharmaceuticals Corporation | $14.82 | 02/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200575471 | CMS |
| Stemline Therapeutics Inc. | $24.16 | 01/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244091776 | CMS |
| Incyte Corporation | $21.10 | 01/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226071333 | CMS |
| Astellas Pharma US Inc | $25.17 | 01/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238760614 | CMS |
| SpringWorks Therapeutics, Inc. | $21.60 | 01/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232171470 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $330.27 | 1 |
| PY2025 | Principal investigator | $2,743,094.44 | 294 |
| PY2024 | Recipient | $8,158.57 | 4 |
| PY2024 | Principal investigator | $2,785,077.00 | 438 |
| PY2023 | Recipient | $284.70 | 2 |
| PY2023 | Principal investigator | $4,850,656.80 | 739 |
| PY2022 | Principal investigator | $6,807,992.86 | 678 |
| PY2021 | Recipient | $4,674.69 | 5 |
| PY2021 | Principal investigator | $4,483,626.39 | 542 |
| PY2020 | Recipient | $9,181.02 | 7 |
| PY2020 | Principal investigator | $3,409,148.90 | 303 |
| PY2019 | Recipient | $17,882.16 | 3 |
| PY2019 | Principal investigator | $4,461,096.48 | 304 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
295 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $71,685.84 | 12/31/2025 | Non-covered Recipient Entity Tennessee Oncology, PLLC | A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1232931302 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $248,671.08 | 12/31/2025 | Non-covered Recipient Entity Tennessee Oncology, PLLC | A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1232931304 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $76,118.93 | 12/31/2025 | Non-covered Recipient Entity Tennessee Oncology | A Phase 1, Dose-Escalation and Expansion Trial of PT2977, A HIF-2a Inhibitor, In Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1232931582 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $808,180.68 | 12/31/2025 | Non-covered Recipient Entity Tennessee Oncology | A Phase 1, Dose-Escalation and Expansion Trial of PT2977, A HIF-2a Inhibitor, In Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1232931756 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $1,221.75 | 12/31/2025 | Non-covered Recipient Entity Sarah Cannon Cancer Institute Nashville | A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1232935819 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $800.00 | 12/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer | No dispute reported | 06/30/2026 | 1185553992 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,248.00 | 12/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175323782 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 12/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252996899 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 12/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252996901 |
| Principal investigator 1 | Nuvation Bio Inc. | $2,500.00 | 12/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC | No dispute reported | 06/30/2026 | 1206087161 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $25,010.94 | 12/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | IL Believe | No dispute reported | 06/30/2026 | 1233998022 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $3,493.01 | 12/15/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | IL Believe | No dispute reported | 06/30/2026 | 1233998026 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $20,741.00 | 12/10/2025 | Non-covered Recipient Entity Tennessee Oncology, PLLC | A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1232931300 |
| Principal investigator 1 | Nuvation Bio Inc. | $2,500.00 | 12/10/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC | No dispute reported | 06/30/2026 | 1206087159 |
| Principal investigator 1 | Genentech, Inc. | $95.00 | 12/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC | No dispute reported | 06/30/2026 | 1211649275 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $112.00 | 12/04/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Phase 1, Open-Label, Dose Finding Study of CC-95251, A Monoclonal Antibody Directed Against SIRPa, Alone and in Combination with Cetuximab or Rituximab in Subjects with Advanced Solid and Hematologic Cancers | No dispute reported | 06/30/2026 | 1235993817 |
| Principal investigator 1 | ModernaTX, Inc. | $5,000.00 | 11/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252996909 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $930.00 | 11/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192143371 |
| Principal investigator 1 | Janssen Research & Development, LLC | $455.00 | 11/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175325575 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $5,078.00 | 11/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649528 |
| Principal investigator 1 | Janssen Research & Development, LLC | $400.00 | 11/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175319211 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $3,000.00 | 10/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649519 |
| Principal investigator 1 | Servier BioInnovation | $624.00 | 10/27/2025 | Non-covered Recipient Entity WCG IRB | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235978143 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $3,000.00 | 10/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649515 |
| Principal investigator 1 | Janssen Research & Development, LLC | $273.00 | 10/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175321981 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,006.00 | 10/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175324863 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $4,086.00 | 10/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649522 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $650.00 | 10/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | IL Believe | No dispute reported | 06/30/2026 | 1233997149 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $650.00 | 09/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192147707 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29.00 | 09/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175319403 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,400.00 | 09/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175323771 |
| Principal investigator 1 | BioNTech SE | $2,500.00 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT-122-01 | No dispute reported | 06/30/2026 | 1249019444 |
| Principal investigator 1 | BioNTech SE | $2,000.00 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT-122-01 | No dispute reported | 06/30/2026 | 1249019446 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $3,000.00 | 09/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649420 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $151.80 | 09/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649431 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 09/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Taiho Phase 1 Study of TAS2940 in Solid Tumors with EGFR and/or HER2 Aberrations [TAS2940-101] - [12TAI2001714] | No dispute reported | 06/30/2026 | 1211415501 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 09/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Taiho Phase 1 Study of TAS2940 in Solid Tumors with EGFR and/or HER2 Aberrations [TAS2940-101] - [12TAI2001714] | No dispute reported | 06/30/2026 | 1211416212 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 09/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Taiho Phase 1 Study of TAS2940 in Solid Tumors with EGFR and/or HER2 Aberrations [TAS2940-101] - [12TAI2001714] | No dispute reported | 06/30/2026 | 1211416214 |
| Principal investigator 1 | Genentech, Inc. | $21,440.00 | 09/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC | No dispute reported | 06/30/2026 | 1211649265 |
| Principal investigator 1 | Genentech, Inc. | $2,400.00 | 09/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC | No dispute reported | 06/30/2026 | 1211649268 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $2,090.00 | 09/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649402 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $175.00 | 09/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649449 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $1,500.00 | 09/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649460 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $3,000.00 | 09/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649506 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $1,167.60 | 09/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | IL Believe | No dispute reported | 06/30/2026 | 1233996731 |
| Principal investigator 1 | Astellas Pharma Global Development | $183.67 | 09/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185834 |
| Principal investigator 1 | Janssen Research & Development, LLC | $600.00 | 09/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175319246 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29.00 | 09/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175319520 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29.00 | 09/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175319801 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29.00 | 09/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175319966 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29.00 | 09/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175322983 |
| Principal investigator 1 | Janssen Research & Development, LLC | $635.00 | 09/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175323425 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29.00 | 09/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175323970 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29.00 | 09/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175324327 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29.00 | 09/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175324594 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29.00 | 09/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175325091 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29.00 | 09/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175326118 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 08/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185822 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 08/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185824 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 08/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185826 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 08/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185828 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 08/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185830 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 08/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185832 |
| Principal investigator 1 | Genentech, Inc. | $900.00 | 08/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1211652023 |
| Principal investigator 1 | Servier BioInnovation | $400.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235973890 |
| Principal investigator 1 | Servier BioInnovation | $2,500.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235973893 |
| Principal investigator 1 | Servier BioInnovation | $296.04 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235973898 |
| Principal investigator 1 | Servier BioInnovation | $1,000.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235973902 |
| Principal investigator 1 | Servier BioInnovation | $1,000.00 | 08/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235973907 |
| Principal investigator 1 | Janssen Research & Development, LLC | $91.00 | 08/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175323855 |
| Principal investigator 1 | BioNTech SE | $2,500.00 | 08/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT-122-01 | No dispute reported | 06/30/2026 | 1249019442 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $175.00 | 08/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649414 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $175.00 | 08/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649418 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $175.00 | 08/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649426 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $175.00 | 08/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649456 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $175.00 | 08/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649481 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $404.28 | 08/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | IL Believe | No dispute reported | 06/30/2026 | 1233996643 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $10,620.00 | 08/11/2025 | Non-covered Recipient Entity Tennessee Oncology | A Phase 1, Dose-Escalation and Expansion Trial of PT2977, A HIF-2a Inhibitor, In Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1232931580 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,090.00 | 08/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192143380 |
| Principal investigator 1 | ModernaTX, Inc. | $450.00 | 08/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252996897 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 08/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) | No dispute reported | 06/30/2026 | 1240585227 |
| Principal investigator 1 | Amgen Inc. | $19,728.25 | 08/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTION LLC | A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation | No dispute reported | 06/30/2026 | 1246647978 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $175.00 | 08/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649406 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $175.00 | 08/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649410 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $175.00 | 08/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649435 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $175.00 | 08/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649440 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $175.00 | 08/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649444 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $175.00 | 08/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649464 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $175.00 | 08/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649468 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $175.00 | 08/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649489 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $175.00 | 08/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649500 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $175.00 | 08/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649503 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $175.00 | 08/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649511 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,208.50 | 07/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185820 |
| Principal investigator 1 | Novocure Inc. | $500.00 | 07/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LL | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma | No dispute reported | 06/30/2026 | 1250856469 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $3,000.00 | 07/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649399 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $3,000.00 | 07/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649424 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $1,500.00 | 07/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649472 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $3,000.00 | 07/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649476 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $2,719.00 | 07/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649485 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $3,060.00 | 07/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649493 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $3,000.00 | 07/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649497 |
| Principal investigator 1 | ModernaTX, Inc. | $5,000.00 | 07/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252996913 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,722.50 | 07/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase 1b/2, Open-label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-Line Therapy in Metastatic Microsatellite-Stable Colorectal Cancer (COLUMBIA 1) | No dispute reported | 06/30/2026 | 1185553982 |
| Principal investigator 1 | Genentech, Inc. | $607.50 | 07/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1211652039 |
| Principal investigator 1 | Blueprint Medicines Corporation | $6,668.00 | 07/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | BLU-945-1101 | No dispute reported | 06/30/2026 | 1235784956 |
| Principal investigator 1 | Genentech, Inc. | $35,524.71 | 07/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211652002 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $650.00 | 07/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | IL Believe | No dispute reported | 06/30/2026 | 1233996547 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $650.00 | 07/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192133714 |
| Principal investigator 1 | Janssen Research & Development, LLC | $273.00 | 07/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175320998 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,400.00 | 07/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | Durvalumab or Placebo in Combination With Gemcitabine Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer TOPAZ-1 | No dispute reported | 06/30/2026 | 1185553998 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $91.00 | 07/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192143363 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,713.00 | 07/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1235993801 |
| Principal investigator 1 | Janssen Research & Development, LLC | $281.00 | 07/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175321703 |
| Principal investigator 1 | BioNTech SE | $2,500.00 | 07/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT-122-01 | No dispute reported | 06/30/2026 | 1249019448 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,200.00 | 06/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175320466 |
| Principal investigator 1 | Amgen Inc. | $30,192.50 | 06/26/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTION LLC | A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression | No dispute reported | 06/30/2026 | 1246647936 |
| Principal investigator 1 | Novocure Inc. | $1,000.00 | 06/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LL | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma | No dispute reported | 06/30/2026 | 1250856311 |
| Principal investigator 1 | Novocure Inc. | $1,200.00 | 06/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LL | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma | No dispute reported | 06/30/2026 | 1250856651 |
| Principal investigator 1 | Servier BioInnovation | $2,304.00 | 06/25/2025 | Non-covered Recipient Entity WCG IRB | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235978137 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $450.00 | 06/20/2025 | Non-covered Recipient Entity Sarah Cannon Cancer Center | A Phase 1/2, Openlabel Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1235993995 |
| Principal investigator 1 | Servier BioInnovation | $1,270.96 | 06/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235973881 |
| Principal investigator 1 | Blueprint Medicines Corporation | $472.00 | 06/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | BLU-945-1101 | No dispute reported | 06/30/2026 | 1235784952 |
| Principal investigator 1 | Servier BioInnovation | $3,909.00 | 06/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235973886 |
| Principal investigator 1 | Genentech, Inc. | $227.25 | 06/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1211651546 |
| Principal investigator 1 | Genentech, Inc. | $3,223.76 | 06/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1211651567 |
| Principal investigator 1 | BioNTech SE | $2,500.00 | 06/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT-122-01 | No dispute reported | 06/30/2026 | 1249019612 |
| Principal investigator 1 | Genentech, Inc. | $3,621.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649627 |
| Principal investigator 1 | Genentech, Inc. | $2,666.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649640 |
| Principal investigator 1 | Genentech, Inc. | $3,290.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649699 |
| Principal investigator 1 | Genentech, Inc. | $4,082.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649701 |
| Principal investigator 1 | Genentech, Inc. | $3,290.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649762 |
| Principal investigator 1 | Genentech, Inc. | $2,185.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649786 |
| Principal investigator 1 | Genentech, Inc. | $5,915.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649792 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) | No dispute reported | 06/30/2026 | 1240585210 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) | No dispute reported | 06/30/2026 | 1240585214 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $525.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON CANCER INSTITUTE AT HDH | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | No dispute reported | 06/30/2026 | 1176545069 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,125.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211415503 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211415505 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,412.26 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211416222 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211416224 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211416226 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211416916 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $4,000.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211416918 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,690.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211417607 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211418327 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211418329 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211418331 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211419739 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,940.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211419741 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $7,500.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211419743 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211419745 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $624.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211420467 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $519.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211420469 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211420471 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,125.00 | 06/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211420473 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $606.42 | 06/04/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | IL Believe | No dispute reported | 06/30/2026 | 1233995875 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $370.00 | 06/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192147711 |
| Principal investigator 1 | Astellas Pharma Global Development | $334.00 | 05/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185818 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $9,833.95 | 05/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC) (MATTERHORN) | No dispute reported | 06/30/2026 | 1185553990 |
| Principal investigator 1 | BioNTech SE | $2,500.00 | 05/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT-122-01 | No dispute reported | 06/30/2026 | 1249019608 |
| Principal investigator 1 | BeiGene, Ltd. | $84.20 | 05/19/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190320788 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $1,747.46 | 05/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | IL Believe | No dispute reported | 06/30/2026 | 1233995647 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,696.00 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175326422 |
| Principal investigator 1 | Janssen Research & Development, LLC | $182.00 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175326618 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 05/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) | No dispute reported | 06/30/2026 | 1240585197 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 05/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) | No dispute reported | 06/30/2026 | 1240585202 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 05/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) | No dispute reported | 06/30/2026 | 1240585219 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 05/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) | No dispute reported | 06/30/2026 | 1240585223 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 05/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) | No dispute reported | 06/30/2026 | 1240585192 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $58,493.34 | 05/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220816796 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,175.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | Phase I Brigimadlin advanced TP53WT/MDM2-amplified tumors | No dispute reported | 06/30/2026 | 1220796635 |
| Principal investigator 1 | Genentech, Inc. | $8,550.00 | 05/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1211650913 |
| Principal investigator 1 | Genentech, Inc. | $2,750.00 | 05/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1211651477 |
| Principal investigator 1 | BioNTech SE | $337.50 | 05/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT-122-01 | No dispute reported | 06/30/2026 | 1249019586 |
| Principal investigator 1 | BioNTech SE | $2,500.00 | 05/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT-122-01 | No dispute reported | 06/30/2026 | 1249019600 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 05/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252996911 |
| Principal investigator 1 | Genentech, Inc. | $4,359.00 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649673 |
| Principal investigator 1 | Genentech, Inc. | $3,888.00 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649694 |
| Principal investigator 1 | Genentech, Inc. | $2,571.00 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649710 |
| Principal investigator 1 | Genentech, Inc. | $3,836.00 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649728 |
| Principal investigator 1 | Genentech, Inc. | $7,950.00 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649779 |
| Principal investigator 1 | Genentech, Inc. | $15,100.00 | 05/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1211650892 |
| Principal investigator 1 | Genentech, Inc. | $12,100.00 | 05/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1211651052 |
| Principal investigator 1 | Genentech, Inc. | $14,100.00 | 05/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1211651106 |
| Principal investigator 1 | Genentech, Inc. | $4,350.00 | 05/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1211651331 |
| Principal investigator 1 | Genentech, Inc. | $4,050.00 | 05/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1211651461 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211416216 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $3,858.00 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211416218 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211416220 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $490.00 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211416908 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211416910 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211416912 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,000.00 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211416914 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $3,421.93 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211417603 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211417605 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211418323 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211418325 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,500.00 | 04/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS-2940 | No dispute reported | 06/30/2026 | 1211419737 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,112.00 | 04/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | No dispute reported | 06/30/2026 | 1226082002 |
| Principal investigator 1 | AstraZeneca UK Limited | $1,600.00 | 04/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2) | No dispute reported | 06/30/2026 | 1185553988 |
| Principal investigator 1 | Janssen Research & Development, LLC | $91.00 | 04/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175321305 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $182.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192133703 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $273.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192133708 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $182.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192143367 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,640.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192143376 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $91.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192143389 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $364.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192143393 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $819.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192147697 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $364.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192147702 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252996893 |
| Principal investigator 1 | ModernaTX, Inc. | $1,100.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252996907 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252996915 |
| Principal investigator 1 | Incyte Corporation | $3,200.00 | 04/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) | No dispute reported | 06/30/2026 | 1240585206 |
| Principal investigator 1 | Genentech, Inc. | $6,344.00 | 04/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph Ia SAD of aLy6G6D in colorectal cancer CRC | No dispute reported | 06/30/2026 | 1211651243 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $7,900.65 | 04/01/2025 | Non-covered Recipient Entity SARAH CANNON CANCER INSTITUTE AT HDH | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | No dispute reported | 06/30/2026 | 1176545047 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $157,600.00 | 04/01/2025 | Non-covered Recipient Entity Tennessee Oncology, PLLC SCRI | An Open-Label Phase 1a,1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1232932643 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $134.38 | 03/31/2025 | Non-covered Recipient Entity Scri Oncology Partners | Phase 1 dose escalation study of BI 765049 mono / combi | No dispute reported | 06/30/2026 | 1220767681 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $134.38 | 03/31/2025 | Non-covered Recipient Entity Scri Oncology Partners | Phase 1 dose escalation study of BI 765049 mono / combi | No dispute reported | 06/30/2026 | 1220767683 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $134.38 | 03/31/2025 | Non-covered Recipient Entity Scri Oncology Partners | Phase 1 dose escalation study of BI 765049 mono / combi | No dispute reported | 06/30/2026 | 1220767685 |
| Recipient | F. Hoffmann-La Roche AG | $330.27 | 03/31/2025 | Covered Recipient Physician | PH III OPEN LABEL STDY ATEZO VS PLATINUM PEMETREXED GEMCITABINE FOR PDL1 CHEMO NAIVE STG IV NSCLC | No dispute reported | 06/30/2026 | 1211535338 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $650.00 | 03/31/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192143385 |
| Principal investigator 1 | Astellas Pharma Global Development | $250.00 | 03/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185812 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 03/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185814 |
| Principal investigator 1 | Astellas Pharma Global Development | $588.00 | 03/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185816 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $15,861.75 | 03/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Durvalumab or Placebo in Combination With Gemcitabine Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer TOPAZ-1 | No dispute reported | 06/30/2026 | 1185553994 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $300.00 | 03/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | Phase I Brigimadlin advanced TP53WT/MDM2-amplified tumors | No dispute reported | 06/30/2026 | 1220796631 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $650.00 | 03/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | Phase I Brigimadlin advanced TP53WT/MDM2-amplified tumors | No dispute reported | 06/30/2026 | 1220796633 |
| Principal investigator 1 | Genentech, Inc. | $2,021.00 | 03/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211650497 |
| Principal investigator 1 | Novocure GmbH | $500.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LL | EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma | No dispute reported | 06/30/2026 | 1250867335 |
| Principal investigator 1 | Novocure GmbH | $1,200.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LL | EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma | No dispute reported | 06/30/2026 | 1250867337 |
| Principal investigator 1 | Novocure GmbH | $1,000.00 | 03/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LL | EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma | No dispute reported | 06/30/2026 | 1250868284 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $38,487.00 | 03/20/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence | No dispute reported | 06/30/2026 | 1235993807 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $28,864.64 | 03/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE ATTN RUSS RUSSELL CONTROLLER | Phase I Brigimadlin advanced TP53WT/MDM2-amplified tumors | No dispute reported | 06/30/2026 | 1220816736 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 03/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) | No dispute reported | 06/30/2026 | 1240585187 |
| Principal investigator 1 | Janssen Research & Development, LLC | $91.00 | 03/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LL C | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175320139 |
| Principal investigator 1 | BioNTech SE | $2,500.00 | 03/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT-122-01 | No dispute reported | 06/30/2026 | 1249019402 |
| Principal investigator 1 | BioNTech SE | $2,500.00 | 03/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT-122-01 | No dispute reported | 06/30/2026 | 1249019733 |
| Principal investigator 1 | Servier BioInnovation | $2,066.00 | 03/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235973870 |
| Principal investigator 1 | Servier BioInnovation | $1,456.00 | 03/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235973876 |
| Principal investigator 1 | Genentech, Inc. | $1,350.00 | 03/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC | No dispute reported | 06/30/2026 | 1211649260 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $23,065.00 | 03/10/2025 | Non-covered Recipient Entity Tennessee Oncology, PLLC | A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(CheckMate 9ER: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9ER | No dispute reported | 06/30/2026 | 1235993337 |
| Principal investigator 1 | Genentech, Inc. | $1,440.00 | 03/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph Ia SAD of aLy6G6D in colorectal cancer CRC | No dispute reported | 06/30/2026 | 1211650804 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 02/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252996905 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $3,000.00 | 02/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649383 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $880.00 | 02/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649387 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $1,537.00 | 02/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649396 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 02/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252996903 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $38,173.74 | 02/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | TAS2940-101 | No dispute reported | 06/30/2026 | 1211415499 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,699.00 | 02/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma | No dispute reported | 06/30/2026 | 1235993815 |
| Principal investigator 1 | ModernaTX, Inc. | $10,825.00 | 02/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252996917 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $9,239.33 | 02/06/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer | No dispute reported | 06/30/2026 | 1235993805 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $30,743.00 | 02/06/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Randomized, Multicenter, Double-Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal or Gastroesophageal Junction Cancer | No dispute reported | 06/30/2026 | 1235993809 |
| Principal investigator 1 | BioNTech SE | $675.00 | 02/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT-122-01 | No dispute reported | 06/30/2026 | 1249019721 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $134.38 | 01/31/2025 | Non-covered Recipient Entity Scri Oncology Partners | Phase 1 dose escalation study of BI 765049 mono / combi | No dispute reported | 06/30/2026 | 1220767675 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $134.38 | 01/31/2025 | Non-covered Recipient Entity Scri Oncology Partners | Phase 1 dose escalation study of BI 765049 mono / combi | No dispute reported | 06/30/2026 | 1220767677 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $134.38 | 01/31/2025 | Non-covered Recipient Entity Scri Oncology Partners | Phase 1 dose escalation study of BI 765049 mono / combi | No dispute reported | 06/30/2026 | 1220767679 |
| Principal investigator 1 | Amgen Inc. | $1,290.00 | 01/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation | No dispute reported | 06/30/2026 | 1246647830 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $300.00 | 01/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | Phase I Brigimadlin advanced TP53WT/MDM2-amplified tumors | No dispute reported | 06/30/2026 | 1220796629 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,082.00 | 01/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Inst Llc | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | No dispute reported | 06/30/2026 | 1226084940 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $90.00 | 01/24/2025 | Non-covered Recipient Entity Sarah Cannon Research Inst Llc | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | No dispute reported | 06/30/2026 | 1226084944 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $16,496.56 | 01/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies | No dispute reported | 06/30/2026 | 1235993803 |
| Principal investigator 1 | Genentech, Inc. | $3,050.00 | 01/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211650618 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 01/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1252996895 |
| Principal investigator 1 | Novocure GmbH | $238.33 | 01/22/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LL | EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma | No dispute reported | 06/30/2026 | 1250867439 |
| Principal investigator 1 | Eisai Inc. | $56.00 | 01/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1244560730 |
| Principal investigator 1 | Eisai Inc. | $56.00 | 01/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1244560734 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $3,000.00 | 01/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1211649391 |
| Principal investigator 1 | Servier BioInnovation | $1,456.00 | 01/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235973851 |
| Principal investigator 1 | Servier BioInnovation | $2,066.00 | 01/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235973856 |
| Principal investigator 1 | Servier BioInnovation | $1,456.00 | 01/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235973861 |
| Principal investigator 1 | Servier BioInnovation | $1,456.00 | 01/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | No dispute reported | 06/30/2026 | 1235973865 |
| Principal investigator 1 | Eisai Inc. | $125.00 | 01/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1244560728 |
| Principal investigator 1 | Eisai Inc. | $125.00 | 01/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1244560732 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $832.00 | 01/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Phase 1/2, Openlabel Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1235993811 |
| Principal investigator 1 | Eli Lilly and Company | $11,197.50 | 01/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 1/2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING RET FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER, AND OTHER TUMORS WITH RET ACTIVATION (LIBRETTO-001) | No dispute reported | 06/30/2026 | 1187887824 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $12,567.00 | 01/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer | No dispute reported | 06/30/2026 | 1185553986 |
| Principal investigator 1 | BioNTech SE | $2,500.00 | 01/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | BNT-122-01 | No dispute reported | 06/30/2026 | 1249019725 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,040.00 | 01/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy ADRIATIC | No dispute reported | 06/30/2026 | 1185553984 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,460.00 | 01/08/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute LLC | Phase I Brigimadlin advanced TP53WT/MDM2-amplified tumors | No dispute reported | 06/30/2026 | 1220796627 |
| Principal investigator 1 | AstraZeneca UK Limited | $380,993.25 | 01/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase 1 Open label Dose escalation and Dose expansion study to evaluate the safety to evaluate the safety tolerability Pharmacokinetics Immunogenicity and Antitumor activity of MEDI5752 in subjects with advanced solid tumors | No dispute reported | 06/30/2026 | 1185553980 |
| Principal investigator 1 | Genentech, Inc. | $2,750.00 | 01/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211650327 |
| Principal investigator 1 | Genentech, Inc. | $349.00 | 01/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211650571 |
| Principal investigator 1 | Genentech, Inc. | $3,500.00 | 01/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211650752 |
| Principal investigator 1 | Genentech, Inc. | $12,650.00 | 01/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211650824 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $10,355.00 | 01/06/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) | No dispute reported | 06/30/2026 | 1235993813 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 01/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUE AT HEALTHONE | A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) | No dispute reported | 06/30/2026 | 1240585183 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $9,012.62 | 01/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC) (MATTERHORN) | No dispute reported | 06/30/2026 | 1185553996 |
| Principal investigator 1 | Genentech, Inc. | $400.00 | 01/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211650283 |
| Principal investigator 1 | Genentech, Inc. | $4,000.00 | 01/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211650305 |
| Principal investigator 1 | Genentech, Inc. | $13,550.00 | 01/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211650357 |
| Principal investigator 1 | Genentech, Inc. | $2,850.00 | 01/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211650417 |
| Principal investigator 1 | Genentech, Inc. | $2,000.00 | 01/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211650800 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.09 | 01/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Phase I Brigimadlin advanced TP53WT/MDM2-amplified tumors | No dispute reported | 06/30/2026 | 1220814281 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.09 | 01/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Phase I Brigimadlin advanced TP53WT/MDM2-amplified tumors | No dispute reported | 06/30/2026 | 1220814283 |